Dr. Roddy McGee on the Joe Rogan Experience #945, fact-checked

What the evidence shows: President Obama's Executive Order 13505, signed March 9, 2009, reversed the Bush administration's 2001 policy that had restricted NIH funding to a limited set of pre-existing embryonic stem cell lines, and NIH guidelines effective July 7, 2009 expanded funding eligibility to additional human embryonic stem cell lines derived from IVF embryos no longer needed for reproductive purposes. However, the order did not lift all restrictions on federal funding for embryonic stem cell research: the Dickey-Wicker Amendment, a recurring appropriations rider in place since 1996, continued (and continues) to bar federal funds from being used to create human embryos for research or to derive stem cells by destroying embryos. Federal funding did expand and continue after 2009 for research using eligible existing stem cell lines, but the characterization that the funding ban was fully "lifted" overstates the order's effect, since a statutory funding bar on embryo creation/destruction remained in place throughout.

What the evidence shows: Rogan cited a study finding a 40% reduction in all-cause mortality tied to sauna use. This matches Laukkanen et al. (2015, JAMA Internal Medicine), a prospective cohort study of 2,315 middle-aged Finnish men followed for a median of 20.7 years: men who used a sauna 4-7 times per week had a multivariable-adjusted hazard ratio of 0.60 for all-cause mortality (929 deaths total), a 40% lower relative risk, compared with men who used one only once per week (the paper itself describes the result as a 40% reduction). That figure is accurate, but it reflects a dose-response comparison among already-habitual Finnish sauna users, not sauna users versus non-users (men who never sauna-bathed were excluded from the cohort), and it applies to middle-aged men in Finland, not a general 'daily use' population claim. The study is observational, and a formal published comment in JAMA Internal Medicine ('The Link Between Sauna Bathing and Mortality May Be Noncausal') argued the association could reflect residual confounding, such as healthier or higher-socioeconomic-status men sauna-bathing more often, rather than a causal effect; the original authors acknowledged this limitation in their reply. Status: the specific number is drawn from a real study and is quoted correctly, but it is presented with more certainty about causation and generalizability than the evidence supports.

What the evidence shows: The guest's figures closely match a widely cited randomized controlled trial (Gosens et al., 2011) comparing platelet-rich plasma (PRP) to corticosteroid injection for chronic lateral epicondylitis (tennis elbow), which reported 73% treatment success in the PRP group versus 49% (by VAS score) or 51% (by DASH score) in the corticosteroid group at one-year follow-up, both differences statistically significant. However, subsequent systematic reviews and meta-analyses of multiple randomized trials show a more time-dependent and mixed picture: corticosteroid injections tend to outperform PRP in the short term (roughly 4-8 weeks), while PRP shows superior pain and function outcomes only at longer follow-up (around 24 weeks and beyond). A review of five systematic reviews found consistent long-term PRP superiority but noted substantial overlap among the underlying primary studies (a 28.3% corrected covered area), meaning the apparent consensus rests on a smaller and less independent evidence base than it appears. The guest's specific numbers are accurate to one real trial, but presenting them without naming the study or acknowledging the short-term/long-term trade-off overstates the certainty of PRP's overall superiority.

What the evidence shows: The claim matches a real 2014 randomized, double-blind, controlled trial (Vangsness et al., Journal of Bone and Joint Surgery) in which 55 patients received a single intra-articular knee injection 7-10 days after partial medial meniscectomy. Contrary to the guest's description, the injected cells were allogeneic (donor-derived) mesenchymal stem cells from a manufactured cell product, not the patient's own bone marrow aspirate concentrate (BMAC). At the 12-month MRI follow-up, a 15% or greater increase in meniscal volume occurred in 24% of patients given the lower cell dose and 6% given the higher dose, versus 0% of controls (p=0.022 for the low-dose comparison). A later narrative review confirms the allogeneic cell source and cites the 24% figure as early clinical evidence, though it does not itself report the 6%/0% comparison figures. No larger confirmatory trial or regulatory approval has followed. The specific "15%" figure is accurate to a real trial, but the guest's account of the intervention (autologous BMAC vs. allogeneic donor cells) is inaccurate, and the finding reflects a modest, early-stage, non-replicated result rather than an established regenerative therapy.

What the evidence shows: The guest stated that 15 to 22 percent of meniscal repairs fail. Peer-reviewed systematic reviews and meta-analyses of arthroscopic meniscal repair report pooled failure rates in a similar range, though the exact figure depends heavily on follow-up length and repair technique. A 2024 meta-analysis of 10 studies (1,004 patients) found a pooled failure rate of 20 percent (95% CI 15-25%) and a reoperation rate of 21 percent. A separate meta-analysis restricted to studies with a minimum 5-year follow-up found an overall failure rate of 19.1 percent, with over a third of failures occurring after the second postoperative year. A third meta-analysis found failure rates rising progressively with time since surgery: 12 percent at 0-1 years, 15 percent at 2-3 years, and 19 percent at 4-6 years. The guest's 15-22 percent figure falls within the range these reviews report, though it should be read as a reasonable point estimate rather than a fixed, universally agreed number, since individual studies vary considerably by tear type, technique, and follow-up duration.

What the evidence shows: The guest recalled a study finding about a 40% failure rate for thermal capsulorrhaphy, a once-popular arthroscopic technique using heat to shrink shoulder capsule tissue for instability, and attributed it to a paper by Richard Hawkins. Published literature confirms this recollection is accurate: Hawkins et al. (Am J Sports Med, 2007; 85 patients, minimum 2-year follow-up) found an overall 43.5% failure rate (37/85), rising to 57-60% for posterior, multidirectional, and combined anteroposterior instability. A separate retrospective cohort (NIH/PMC review) reported a 31% overall failure rate at a mean 39-month follow-up, with failure rates varying sharply by instability type: 80% for posterior instability versus 28% for multidirectional instability. That review also noted chondrolysis (cartilage death) as a serious complication reported with increasing frequency over time, and concluded the procedure could not be recommended for most instability patients. Overall status: well-supported, both on the approximate 40% failure figure and on the claim that the procedure fell out of favor as a result.